(R)-3-Amino-1-Butanol CAS 61477-40-5 Purity >99.0% (GC) Dolutegravir Intermediate Factory

Chemical Name: (R)-3-Amino-1-Butanol Synonyms: (R)-3-Aminobutan-1-ol  CAS: 61477-40-5 Purity: >99.0% (GC)  Appearance: Colorless to Light Yellow Liquid   Intermediate of Dolutegravir (CAS: 1051375-16-6) E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Fluorinated Bottle, 25kg/Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureShanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (R)-3-Amino-1-Butanol (CAS: 61477-40-5) with high quality, commercial production. It's an intermediate of Dolutegravir (CAS: 1051375-16-6). We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available, strong after-sale service. Please contact: alvin@ruifuchem.com

Appearance

Colorless to Light Yellow Liquid

Light Yellow Liquid

Identification by IR

Conforms to Spectrum of the Standard

Conforms

Identification by GC

Conforms to Retention Time of the Standard

Conforms

Purity by GC (A%)

>99.0%

99.8%

Related Substances

Any Single Impurity: <0.5%

0.09%

Total Impurities: <1.0%

0.28%

S-Isomer (by HPLC A%)

<0.10%

0.02%

Water Content by KF

<0.50%

0.10%

Assay by GC (w/w%)

>99.0%

99.3%

Description:

Specifications:

Package & Storage:

Chemical Name (R)-3-Amino-1-Butanol
Synonyms (R)-3-Aminobutan-1-ol; (3R)-3-Amino-1-Butanol
CAS Number 61477-40-5
CAT Number RF-CC317
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C4H11NO
Molecular Weight 89.14
Specific Gravity (20/20) 0.95
Refractive Index 1.45
Specific Rotation [α]20/D -12.0° ~ -10.0° (C=1, EtOH)
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

(R)-3-Amino-1-Butanol (CAS: 61477-40-5) can be used as an intermediate in the preparation of compounds having HIV integrase inhibitory activity. (R)-3-Amino-1-Butanol is an intermediate of Dolutegravir (CAS: 1051375-16-6). Dolutegravir (Tivicay) was a new kind of anti-ADIS drug that jointly developed by the British pharmaceutical giant GlaxoSmithKline (GSK) with the Japanese Shionogi Pharmaceutical Company (Shionogi). In August 2013, the US FDA approved dolutegravir (also referred to as S/GSK1349572) for the treatment of HIV-1 infection in adults and children ages 12 years and older in combination with other antiretroviral drugs.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours